NCT03028285View on ClinicalTrials.gov

Study of Safety and Tolerability of UNIFUZOL (Solution for Infusions) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 15, 2016

Primary Completion Date

January 19, 2017

Study Completion Date

January 26, 2017

Conditions
Peripheral Vascular Disease
Interventions
DRUG

arginine sodium succinate

Healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at 3 different combinations of dose and infusion rate under the close monitoring of vital signs and other safety parameters.

Trial Locations (2)

109240

Clinical diagnostic laboratory of City Clinical Hospital named after I.V.Davydovsky, Moscow

196143

Research Center for Eco-safety, Ltd., Saint Petersburg

All Listed Sponsors
lead

POLYSAN Scientific & Technological Pharmaceutical Company

INDUSTRY

NCT03028285 - Study of Safety and Tolerability of UNIFUZOL (Solution for Infusions) in Healthy Volunteers | Biotech Hunter | Biotech Hunter